PTIX
Protagenic Therapeutics, Inc.1.5200
-0.0699-4.4%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
2.93MP/E (TTM)
-Basic EPS (TTM)
-13.13Dividend Yield
0%Recent Filings
10-Q
8-K
8-K
8-K
Auditor switch and Nasdaq notice
Protagenic Therapeutics switched auditors on August 7, 2025, dismissing MaloneBailey for Green Growth amid a clean transition with no disagreements, though the prior report flagged going concern doubts. The company faces Nasdaq non-compliance from a delayed Q2 10-Q filing due to merger accounting complexities, yet trading continues uninterrupted while they plan to submit a compliance plan. First doses completed in the PT00114 Phase I trial. Topline data due by September end.
8-K
Restructuring prioritizes clinical trial
Protagenic Therapeutics approved a restructuring plan on August 8, 2025, to shift to a virtual model and prioritize its Phase 2 trial of PT00114, expected to wrap in 9-12 months. The plan suspends preclinical programs for potential partnerships, cuts annualized expenses by $8 million, and terminates CEO Barrett Evans and COO Colin Stott—yet they stay on the board. One-time charges loom undetermined. This sharpens focus on clinical assets amid cash conservation.
CPMV
Mosaic ImmunoEngineering Inc.
0.40+0.00
EPIX
ESSA Pharma Inc.
0.20+0.00
IMA
ImageneBio, Inc.
6.25+0.08
PKTX
ProtoKinetix, Inc.
0.00+0.00
PLX
Protalix BioTherapeutics, Inc.
1.81+0.07
PNXP
Pineapple Express Cannabis Comp
0.01+0.00
PPCB
Propanc Biopharma, Inc.
0.73-0.03
PTGX
Protagonist Therapeutics, Inc.
91.54-3.25
TARA
Protara Therapeutics, Inc.
5.42-0.08
XCUR
Exicure, Inc.
6.06+0.33